Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience has launched a 12-week Phase 1b study to assess if its DehydraTECH technology can enhance the safety and effectiveness of GLP-1 drugs, potentially reducing side effects and improving efficacy. This study, involving various capsules and tablets, aims to provide significant insights into diabetes control and weight loss management. Conducted across seven sites in Australia, the study’s findings may align with FDA standards.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.